Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Flow cytometric analysis of Anti-CD20 CAR-293 cells staining with FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) at 1 μg/mL (1 μg/mL corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with negative control protein. FITC signal was used to evaluate the binding activity (QC tested).
FACS assay shows that Monoclonal Anti-Human CD20 Full Length Antibody, Human IgG1 can bind to HEK293/Human CD20 Stable Cell Line. HEK293/Human CD20 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).
Obinutuzumab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 23.4 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Rituximab biosimilar (Reliance Life Sciences) | R-TPR-017 | Approved | Reliance Life Sciences | Toritz, RituxiRel | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | null | 2016-01-01 | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Center of Molecular Immunology) | Approved | Center Of Molecular Immunology | CIMAbior, RituxCIM | Cuba | Lymphoma, Non-Hodgkin | null | 2017-04-01 | Lymphoma, Non-Hodgkin | Details | |
rituximab biosimilar (Zenotech) | Approved | Zenotech Laboratories | India | Lymphoma, Non-Hodgkin | Zenotech Laboratories | 2013-02-01 | Lymphoma, Non-Hodgkin | Details | ||
Rituximab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Mabtas | India | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Intas Biopharmaceuticals | 2013-01-01 | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Biosidus) | Approved | Biosidus | Argentina | Hematologic Neoplasms | Biosidus | 2013-06-01 | Hematologic Neoplasms | Details | ||
Rituximab biosimilar (Probiomed) | PBO-326 | Approved | Probiomed | Kikuzubam | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | ||||
Rituximab biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Zytux | Iran | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis | Aryogen Biopharma | 2014-01-01 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | |
Hyaluronidase/Rituximab | Approved | Genentech Inc | Rituxan Hycela | United States | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Genentech Inc | 2017-06-22 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Dr Reddy's Laboratories) | Approved | Dr Reddy's Laboratories Ltd | Reditux, Tidecron | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | Dr Reddy's Laboratories Ltd | 2007-01-01 | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Hetero Drugs) | Approved | Hetero Drugs Ltd | Maball, Mabura | India | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Hetero Drugs Ltd | 2015-01-01 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Biocad) | BCD-020 | Approved | Biocad | Acellbia | Russian Federation | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Biocad | 2015-01-01 | Lymphoma, B-Cell, Marginal Zone; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Ripertamab | SCT-400 | Approved | SinoCelltech Ltd | Mainland China | Lymphoma, Non-Hodgkin | SinoCelltech Ltd | 2022-08-23 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
Rituximab biosimilar (Pfizer) | PF-05280586; PF-5280586 | Approved | Pfizer Pharmaceuticals Ltd (China) | Ruxience | EU | Lymphoma, Non-Hodgkin; Pemphigus; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis | Pfizer Europe Ma Eeig | 2019-07-23 | Lymphoma, T-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic-Phase; Burkitt Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Biphenotypic, Acute; Pemphigus; Lymphoma, B-Cell; Multiple Myeloma; Arthritis, Rheumatoid; Leukemia, Myelomonocytic, Chronic; Lymphoma, AIDS-Related; Hodgkin Disease; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Microscopic Polyangiitis; Anemia, Refractory, with Excess of Blasts; Anemia; Leukemia, Lymphoid; Granulomatosis with Polyangiitis; Leukemia, Myeloid, Accelerated Phase; Lymphoma, B-Cell, Marginal Zone; Bone Marrow Neoplasms | Details |
Rituximab biosimilar (Amgen) | APB-798; ABP-798 | Approved | Amgen Inc | Riabni | United States | Arthritis, Rheumatoid | Amgen Inc | 2020-12-17 | Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell; Plasmablastic Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Chronic-Phase; Lymphoproliferative Disorders; Lymphoma, Follicular; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Biphenotypic, Acute; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Hematologic Neoplasms; Bone Marrow Neoplasms; Microscopic Polyangiitis; Anemia; Anemia, Refractory, with Excess of Blasts; Granulomatosis with Polyangiitis; Neoplasms; Hodgkin Disease; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Arthritis, Rheumatoid; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm | Details |
Rituximab biosimilar (mAbxience) | RTXM-83; mAbx-02 | Approved | Mabxience Sa | Novex | Argentina | Lymphoma, Large B-Cell, Diffuse | Mabxience Sa | 2015-01-01 | Lymphoma, B-Cell, Marginal Zone; Anemia; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Leukemia, B-Cell; Lymphoma, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Ofatumumab | OMB-157; HuMax-CD2; GSK-1841157; 2F2 | Approved | Genmab A/S | Arzerra, Kesimpta | Mainland China | Multiple Sclerosis, Relapsing-Remitting | Beijing Novartis Pharma Co Ltd | 2009-10-26 | Leukemia; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Multiple Sclerosis; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
Ocrelizumab | R-1594; RG-1594; PRO-70769; RO-4964913; rhuMab 2H7 | Approved | Genentech Inc | Ocrevus | EU | Multiple Sclerosis | Roche Registration Gmbh | 2017-03-28 | Multiple Sclerosis, Relapsing-Remitting; Schizophrenia; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Encephalitis | Details |
Rituximab | R-105; RG-105; IDEC-102; IDEC-C2B8; RO-452294 | Approved | Biogen Inc | 美罗华, Ristova, Rituxan, MabThera, MabThera/Rituxan | EU | Burkitt Lymphoma; Lymphoma, Large B-Cell, Diffuse | Roche Registration Gmbh | 1997-11-26 | Granulomatosis with Polyangiitis; Rejection of renal transplantation; Purpura, Thrombocytopenic, Idiopathic; Peripheral Nervous System Diseases; Lymphoma, B-Cell, Marginal Zone; Leukemia; Lymphoma, B-Cell; Myasthenia Gravis; Liver Cirrhosis, Biliary; Ocular Motility Disorders; Polymyositis; Diabetes Mellitus, Type 1; Opsoclonus-Myoclonus Syndrome; Multiple Sclerosis, Relapsing-Remitting; Hematologic Neoplasms; HIV Infections; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Keratoconjunctivitis Sicca; Rejection of liver transplantation; Microscopic Polyangiitis; Nephrosis; Schizophrenia; Dermatomyositis; Pulmonary Alveolar Proteinosis; Stomach Neoplasms; Myositis; ST Elevation Myocardial Infarction; Scleritis; Renal Insufficiency; Hemophilia A; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Sarcoidosis; Psychotic Disorders; Lymphoma, AIDS-Related; Lymphomatoid Granulomatosis; Autoimmune Diseases; Anemia, Diamond-Blackfan; Fatigue; Spondylitis, Ankylosing; Red-Cell Aplasia, Pure; Colonic N | Details |
Mosunetuzumab | RG-7828; BTCT-4465A; RO-7030816 | Approved | Genentech Inc | Lunsumio | EU | Lymphoma, Follicular | Roche Registration Gmbh | 2022-06-03 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Obinutuzumab | RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 | Approved | Genentech Inc | Gazyva, Gazyvaro, Gazyva/Gazyvaro, 佳罗华 | EU | Lymphoma, Follicular | F. Hoffmann-La Roche Ltd | 2013-11-01 | Glomerulosclerosis, Focal Segmental; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoproliferative Disorders; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lupus Nephritis; Glomerulonephritis, Membranous; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphoid; Nephrosis; Lymphoma, B-Cell; Leukemia | Details |
Rituximab biosimilar (Shanghai Henlius Biotech) | HLX-01 | Approved | Shanghai Henlius Biotech Co Ltd | 汉利康 | Mainland China | Arthritis, Rheumatoid | Shanghai Henlius Biotech Co Ltd | 2019-02-22 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Sandoz) | GP-2013 | Approved | Sandoz | Riximyo, Rixathon | Japan | Microscopic Polyangiitis; Lymphoma, Non-Hodgkin; Granulomatosis with Polyangiitis | Clariant Produkte (Schweiz) Ag | 2017-06-15 | Lymphoma, B-Cell; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Innovent Biologics) | IBI-301 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达伯华, HALPRYZA | Mainland China | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Innovent Biologics(Suzhou) Co Ltd | 2020-09-30 | Lymphoma, Follicular; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Burkitt Lymphoma; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Leukemia, Myeloid, Chronic-Phase; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Hematologic Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Multiple Myeloma; Neoplasms; Leukemia, Myelomonocytic, Chronic; Hodgkin Disease; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Anemia, Refractory, with Excess of Blasts; Anemia; Leukemia, Myeloid, Accelerated Phase; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Bone Marrow Neoplasms | Details |
Ibritumomab tiuxetan | IDEC-In2B8; BAY86-5128; SHL-749; IDEC-129; IDEC-2B8-MX-DTPA; IDEC-Y2B8 | Approved | Biogen Inc | Zevalin, Zavalin | Japan | Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell | Mundipharma Kk | 2002-02-19 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Celltrion) | CT-P10 | Approved | Celltrion Inc | Truxima, Blitzima, Ritemvia, Rituzena | United States | Lymphoma, Non-Hodgkin | Celltrion Inc | 2017-02-17 | Lymphoma, Follicular; Pemphigus; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Lymphoma; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Leukemia, Myeloid, Chronic-Phase; Lymphoproliferative Disorders; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Bone Marrow Neoplasms; Multiple Myeloma; Leukemia, Myelomonocytic, Chronic; Hodgkin Disease; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Microscopic Polyangiitis; Leukemia, Lymphoid; Anemia, Refractory, with Excess of Blasts; Anemia; Granulomatosis with Polyangiitis; Leukemia, Myeloid, Accelerated Phase; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
Rituximab biosimilar (International Biotech Center Generium) | GNR-006 | Phase 1 Clinical | International Biotech Center Generium | Lymphoma, B-Cell | Details |
Rituximab biosimilar (Gedeon Richter) | RGB-03 | Phase 1 Clinical | Gedeon Richter | Arthritis, Rheumatoid | Details |
Bendamustine Hydrochloride/Rituximab | Phase 1 Clinical | 1globe Biomedical Co Ltd | Lymphoma, B-Cell | Details | |
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) | Phase 2 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan Bio-Raid Biotechnology | Neoplasms | Details | |
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details | |
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) | LZM-002 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar(Shandong New Time Pharmaceutical) | H-02; F-007 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
JMT-601 | JMT-601 | Phase 1 Clinical | Shanghai Jinmante Biological Technology Co Ltd | Lymphoma, Non-Hodgkin | Details |
EX-103 | EX-103; EX103 | Phase 1 Clinical | Guangzhou ASM Biomedical Technology Co Ltd | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar(Bioxpress) | BXT-2336 | Clinical | Bioxpress Therapeutics Sa | Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
Anti-CD20 CAR-T cell therapy (Beijing Biohealthcare Biotechnology) | Beijing Biohealthcare Biotechnology Co Ltd | Details | |||
CPO-107 | Conjupro Biotherapeutics Inc | Details | |||
QLP-31907 | QLP-31907; QLP31907; PSB-202 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lymphoma, B-Cell | Details |
MRG001 | MRG-001 | Phase 1 Clinical | Shanghai Miracogen Inc | Lymphoma, Non-Hodgkin | Details |
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) | Shanghai Longyao Biological Technology Co Ltd | Details | |||
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) | PBCAR-20A | Precision Biosciences Inc | Details | ||
BAT-4406F | BAT-4406; BAT-4406F | Phase 1 Clinical | Bio-Thera Solutions Ltd | Neuromyelitis Optica | Details |
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) | B001 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Neuromyelitis Optica; Lymphoma; Lymphoma, Non-Hodgkin | Details |
Ocrelizumab biosimilar (CinnaGen) | Cinnagen | Details | |||
Divozilimab | BCD-132 | Biocad | Details | ||
SBI-087 | SBI-087; PF-5230895; PF-05230895 | Emergent | Details | ||
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Fujian Medical University | Details | |||
PRO-131921 | PRO-131921 | Genentech Inc | Details | ||
TRS-005 | TRS-005 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma, Non-Hodgkin | Details |
MT-3724 | MT-3724 | Molecular Partners Ag | Details | ||
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) | BAT-4306F | Phase 1 Clinical | Bio-Thera Solutions Ltd | Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) | TRS001 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma | Details |
MB-CART20.1 (Miltenyi Biotec) | Phase 1 Clinical | Miltenyi Biotec | Melanoma | Details | |
GB-261 | GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
BVX20-CD20 antibody (Biocon/Vaccinex) | BVX-20; BVX20-MAb | Phase 2 Clinical | Biocon Ltd, Vaccinex Inc | Lymphoma, Non-Hodgkin | Details |
SNG2005 | SNG-2005 | Phase 1 Clinical | Alopexx Oncology Llc | Lymphoma, B-Cell | Details |
bbT-369 | bbT-369 | Phase 2 Clinical | Bluebird Bio Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
C-CAR039 | EXP-039; C-CAR039; C-CAR-039 | Phase 1 Clinical | Lymphoma, Non-Hodgkin | Details | |
CAR-20-19-22 | CAR-20-19-22 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
MB-CART19.1 (Miltenyi Biotec) | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, Large B-Cell, Diffuse | Details |
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin | Details | |
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Lymphoma, B-Cell; Leukemia, B-Cell | Details | ||
Rituximab biosimilar (Hualan Biological Engineering) | WBP-263 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | CAR-20/19-T cells | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD20-directed CAR-T cell therapy (Tongji Hospital) | C-CAR066 | Phase 1 Clinical | Tongji Hospital | Lymphoma, B-Cell | Details |
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) | LUCAR-20S | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, Large B-Cell, Diffuse; Multicentric Castleman's Disease (MCD); Burkitt Lymphoma; Sarcoma, Kaposi | Details | |
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) | Phase 1 Clinical | Henan Provincial Cancer Hospital | Lymphoma, B-Cell | Details | |
CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Persongen Biotherapeutics | Details | ||
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) | B-007 | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Nephrosis; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
TQB-2825 | TQB-2825 | Phase 1 Clinical | Wuxi Biologics Co Ltd | Hematologic Neoplasms; Neoplasms | Details |
1-A-46 | 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Rituximab Biosimilar (Istituto Giannina Gaslini) | Phase 2 Clinical | Istituto Giannina Gaslini | Nephrotic Syndrome | Details | |
Imvotamab | IGM-2323 | Phase 2 Clinical | Igm Biosciences Inc | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Iodine 131 tositumomab | TST/I131-TST | Phase 3 Clinical | Glaxosmithkline Plc | Lymphoma, B-Cell; Leukemia, Lymphoid; Hodgkin Disease; Multiple Myeloma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Genor Biopharma) | GB-241 | Phase 3 Clinical | Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Chronic-Phase; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Multiple Myeloma; Myelodysplastic Syndromes; Hodgkin Disease; Leukemia, Myelomonocytic, Chronic; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Anemia, Refractory, with Excess of Blasts; Bone Marrow Neoplasms; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase | Details |
Rituximab biosimilar (JHL Biotech) | JHL-1101 | Phase 2 Clinical | JHL Biotech | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (CTTQ Pharma) | TQB-2303 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Lymphoma, T-Cell | Details |
Rituximab biosimilar (Boehringer Ingelheim) | BI-695500 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Lymphoma, Follicular; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic-Phase; Leukemia, B-Cell; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Multiple Myeloma; Arthritis, Rheumatoid; Myelodysplastic Syndromes; Hodgkin Disease; Neoplasms; Leukemia, Myelomonocytic, Chronic; Lymphoma, Large B-Cell, Diffuse; Anemia, Refractory, with Excess of Blasts; Anemia; Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Lymphoma, B-Cell, Marginal Zone | Details |
Rituximab biosimilar (Samsung) | SAIT-101 | Phase 3 Clinical | Samsung Biologics Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic-Phase; Leukemia, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Arthritis, Rheumatoid; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Anemia, Refractory, with Excess of Blasts; Anemia; Lymphoma, B-Cell, Marginal Zone; Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase | Details |
Plamotamab | XmAb-13676 | Phase 2 Clinical | Xencor Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ACE-1831 | ACE-1831 | Phase 1 Clinical | Acepodia Biotech Inc | Lymphoma, Non-Hodgkin | Details |
ADI-001 | ADI-001 | Phase 1 Clinical | Adicet Bio Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma | Details |
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell | Details | |
Rituximab Biosimilar(Shanghai Institute Of Biological Products) | SIBP-02 | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
MB-106 | MB-106 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
UCART-20x22 | UCART-20x22 | Phase 2 Clinical | Cellectis Sa | Lymphoma, Non-Hodgkin | Details |
Odronextamab | REGN-1979 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
LY007 | LY007 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
IMM-0306 | IMM-0306 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Lymphoma, B-Cell | Details |
CD20 monoclonal antibody(The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Anemia, Aplastic | Details | |
JS-203 | JS-203 | Phase 1 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
KITE-363 | KITE-363 | Phase 1 Clinical | Kite Pharma | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details |
Glofitamab | RO-7082859; RG-6026 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma | Details |
TanCART19/20 | Phase 1 Clinical | Pla General Hospital | Neuromyelitis Optica | Details | |
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) | CART-20; CBM-C20.1; CBM-CD20 1 | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CM-355(Beijing Tiannuo Jiancheng/Connaught Biomedical Technology) | CM-355 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
Recombinant humanized monoclonal antibody MIL62 | MIL62 | Phase 3 Clinical | Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Nephrosis; Lupus Nephritis; Glomerulonephritis, Membranous; Lymphoma, Follicular; Neuromyelitis Optica; Lymphoma, Non-Hodgkin | Details |
MBS-303 | MBS-303 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell | Details |
This web search service is supported by Google Inc.